Upstream Bio, Inc. operates as a clinical-stage biotechnology company. The Company focuses on developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Upstream Bio serves customers in the United States.

S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Upstream Bio (UPB US)

S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers

Quarterly Report (Form 10-Q | Period ending 2025-09-30)

Current Report (Form 8-K | Period ending 2025-11-05)

Current Report (Form 8-K | Period ending 2025-09-02)

Quarterly Report (Form 10-Q | Period ending 2025-06-30)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)